Research programme: RNA therapeutics - Arcturus Therapeutics/Takeda

Drug Profile

Research programme: RNA therapeutics - Arcturus Therapeutics/Takeda

Alternative Names: LUNAR-GI

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Arcturus Therapeutics
  • Class MicroRNAs; RNA; Small interfering RNA
  • Mechanism of Action RNA interference; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Dec 2016 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)
  • 06 Dec 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top